Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy

NCT ID: NCT01330693

Last Updated: 2015-08-19

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-09-30
• Study Completion Date: 2015-11-30

Brief Summary

The purpose of this study is to find out if children with attention-deficit, hyperactivity disorder (ADHD) have a difference in how their brain cells "fire" or react. The investigators also want to find if brain cell "firing" can tell us how severe of symptoms a child has from ADHD. Finally, the investigators want to see if giving an ADHD medication called atomoxetine can make the ADHD symptoms in a child better and if the improvement shows a change in brain "firing".

Detailed Description

This study will evaluate Short Interval Intracortical Inhibition (SICI) measured by pTMS as a marker of the hyperactive-impulsive dimension in 120 ADHD 7-12 years, medication-free children. This study will characterize the effects of a single dose of atomoxetine compared to placebo on cognitive correlates of SICI change. Participants will be randomized 2:1 to either atomoxetine or placebo. The study will also characterize the effects of four weeks of atomoxetine treatment on cortical inhibition and will correlate SICI change with clinical outcomes.

Conditions

Attention Deficit Disorder With Hyperactivity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Atomoxetine

Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children

Group Type: ACTIVE_COMPARATOR

Atomoxetine

Intervention Type: DRUG

Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.

Placebo

Sugar pill

Group Type: PLACEBO_COMPARATOR

Sugar Pill

Intervention Type: DRUG

In-active sugar pill randomly assigned at baseline visit

Interventions

Atomoxetine

Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.

Intervention Type: DRUG

Sugar Pill

In-active sugar pill randomly assigned at baseline visit

Intervention Type: DRUG

Other Intervention Names

Strattera

Eligibility Criteria

Inclusion Criteria

1. Signed informed consent and assent

2. Meets DSM-IV criteria for ADHD, combined or inattentive subtype, based on K-SADS interview

3. Scores at least 1.5 SD higher than age and gender mean on ADHD RS, keyed to ADHD subtype (i.e., combined score for the combined subtype, inattentive subscale only for inattentive subtype, etc.)

4. Age: 7 - 12 years at study entry

5. Findings on physical exam, laboratory studies and ECG are judged to be normal for age and gender, as determined by study physician at study entry

6. There is not a co-existing medical condition for which TMS or ATX is contraindicated (for example pheochromocytoma).

7. Pulse and blood pressure within 95% of age and gender mean

8. Full scale IQ >75 (i.e., excluding mental retardation and the lower level of the borderline range)

9. Able to complete study instruments and swallow capsules

10. Willing to commit to the entire visit schedule for the study

11. No previous treatment with Atomoxetine

12. Must either be naive to ADHD study medication or not doing well on the current ADHD medication.

Exclusion Criteria

1. Has one of the following exclusionary diagnoses: autism/ pervasive developmental disorder, mental retardation, schizophrenia, a psychotic disorder, bipolar disorder, severe depressive or conduct disorder

2. Has a comorbid disorder that is otherwise allowable, but which requires a treatment that is not being offered in the study, and should be the primary focus of treatment, in the opinion of the PI

3. Has a medical or neurologic disorder that would preclude taking the ATX, or which would potentially confound the assessment of ADHD and/or TMS outcomes, in the opinion of the PI (for example pheochromocytoma, or for specific purposes of this study uncontrolled seizure disorder or organic brain syndrome).

4. Taking a systemic medication which might interfere with the metabolism or efficacy assessment of ATX in this study

5. History of allergic reactions to multiple medications

6. History of alcohol or drug abuse in the past 3 months Has been in a medication treatment study in the past 30 days

7. Females of childbearing age who are sexually active, do not use acceptable birth control (double barrier method), or are not abstinent. Abstinence is defined as no sexual activity for at least 3 months before the start of the study and the intention to abstain from sexual activity during the study period). Double barrier methods allowed include: condoms or diaphragms combined with spermicide use, intrauterine devices (IUD), and oral, transdermal, injectable or implantable hormonal medications (Ortho-Evra, Norplant, Depo-Provera, and similar prescription products) for at least one month before entering the study and continuing its use throughout the study. Birth control pills alone are not acceptable forms of birth control for this study.

8. Has any prior neurological condition that might increase the risk of an adverse event with TMS. For the purpose of this study we are excluding children with a current or prior history of epilepsy.

• Minimum Eligible Age: 7 Years
• Maximum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Mental Health (NIMH)

NIH

Sponsor Role: collaborator

University of Cincinnati

OTHER

Sponsor Role: lead

Responsible Party

Floyd Sallee

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Floyd R Sallee, MD

Role: PRINCIPAL_INVESTIGATOR

University of Cincinnati

Locations

University of Cincinnati

Cincinnati, Ohio, United States

Cincinnati Children's Hospital

Cincinnati, Ohio, United States

Countries

United States

Other Identifiers

1R01MH081854-01A2

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1R01MH081854-01A2

Identifier Type: NIH

Identifier Source: org_study_id

View Link